ClinicalTrials.gg
RecruitingNCT07284472SERENADAUpdated Nov 6, 2026

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

A Phase 2/3 interventional study of EXV-802 and Placebo in Agitation Associated With Alzheimer's Disease Dementia, sponsored by Exciva GmbH. Recruiting at 49 sites in 9 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Exciva GmbH · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 6, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 113 studies in Alzheimer Disease with a site in Poland — 15 open to participants now, 25 under way, 14 of them phase 3. Alzheimer Disease · Poland.

Planned enrollment
78th of 111
300 · median 500
Started
2026
with 3 others
Phase 2/3
4 of 113
1 open now
Primary completion
2029-01
later than 19 of 24 live
Registered
111th of 113
by date

Among the 113 studies in Alzheimer Disease with a site in Poland, this one is the 78th largest by planned enrollment of the 111 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2/3, reaches primary completion later than 19 of the 24 other live ones, and was the 111th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

15 of the 113 studies in Alzheimer Disease with a site in Poland are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Alzheimer Disease with a site in Poland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Read the detailed description

This is a Phase 2/3 multicenter, double-blind, placebo-controlled, three-arm, multicenter study evaluating the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia. The diagnosis of agitation will be based on the consensus definition for agitation in patients with cognitive disorders developed by te International Psychogeriatric Association (IPA) Agitation Definition Work Group as well as neuroimaging performed after onset of dementia symptoms and a Core 1 AD biomarker.

The study will be conducted at up to 60 centers in the US, Canada and Europe.. Screening will occur within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study. Approximately 100 patients per arm will be randomized (300 total).

03

Conditions studied

  • Agitation Associated With Alzheimer's Disease Dementia
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair.
  2. A previously established diagnosis of AD dementia.
  3. The participant has , moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization
  4. The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
  5. Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day.

Exclusion criteria

Exclusion criteria:

  1. The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia.
  2. The participant has symptoms of agitation that are not secondary to AD dementia
  3. The participant has a history of uncontrolled seizures or a history of epilepsy.
  4. The participant has a major medical illness or unstable medical condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    EXV-802

    Participants will be assigned to treatment with EXV-802 capsules administered twice a day over a 6-week period.

    Drug: EXV-802

  • Placebo comparator
    Placebo

    Participants will be assigned to treatment with placebo capsules administered twice a day over a 6-week period.

    Drug: Placebo

  • Experimental
    EXV-801

    Participants will be assigned to treatment with EXV-801 capsules administered twice a day over a 6-week period.

    Drug: EXV-801

Interventions

  • DrugEXV-802

    Specified dose twice daily

    Also known as: Dextromethorphan + EXV-801

  • DrugPlacebo

    Specified dose twice daily

  • DrugEXV-801

    Specified dose twice daily

    Also known as: deramciclane

06

What researchers measure

Primary outcomes

  1. Changes from baseline to endpoint (Week 6) in the Cohen-Mansfield Agitation Inventory - International Psychogeriatric Association (CMAI-IPA) score

    The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviors while lower scores indicate lower frequency of agitated behaviors The CMAI-IPA includes 19 items that were mapped to IPA agitation domains. The total score ranges from 19 to 133 with higher scores indicating more severity.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Changes from baseline to endpoint (Week 6) in the Clinical Global Impression of Severity of Illness (CGI-S) score as related to symptoms of agitation

    The CGI-S is an observer-rated scale that measures illness severity. The CGI-S is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = extremely ill) that assessed the severity of agitation in this study. Higher scores indicate severe agitation, while the lower scores indicate little or no agitation.

    Time frame: Baseline to Week 6

Other outcomes

  1. Changes from baseline to endpoint (Week 6) in the Neuropsychiatric Inventory - Clinician (NPI-C) Caregiver Distress score for Agitation and Aggression domains

    The NPI-C is a retrospective interview covering 14 neuropsychiatric symptom domains. The NPI-C version of the NPI scale was designed to be administered by the clinician to the participant and the caregiver. The caregiver is first asked to provide frequency, severity, and distress ratings for each individual item across the domains. Frequency is rated on a scale from 0 to 4. Severity is rated on a scale from 0 to 3. Separately, the rater interviews the patient to assess frequency (0 to 4) of each item. Clinician rating of clinical impression is a severity rating (0 to 3) based on all available clinical and interview information. For this endpoint, the caregiver distress will be analyzed for the agitation and aggression domains. Caregiver distress is rated on a scale from 0 to 5 with a total score range of 0 to 10 across the 2 domains. Higher scores indicate greater caregiver distress.

    Time frame: Baseline to Week 6

  2. Changes from baseline to endpoint (Week 6) in the Neuropsychiatric Inventory - Clinician (NPI-C) Irritability/Liability Domain score

    The NPI-C is a retrospective interview covering 14 neuropsychiatric symptom domains. The NPI-C version of the NPI scale was designed to be administered by the clinician to the participant and the caregiver. The caregiver is first asked to provide frequency, severity, and distress ratings for each individual item across the domains. Frequency is rated on a scale from 0 to 4. Severity is rated on a scale from 0 to 3. Separately, the rater interviews the patient to assess frequency (0 to 4) of each item. Clinician rating of clinical impression is a severity rating (0 to 3) based on all available clinical and interview information. The score for the irritability/lability domain is the sum of clinical impression ratings of all items. There are 12 items in the irritability/lability domain. The minimum score for the irritability/lability domain is 0 and maximum score per domain is 36, with higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 6

  3. Changes from baseline to endpoint (Week 6) in the Neuropsychiatric Inventory - Clinician (NPI-C) Sleep Disorders Domain score

    The NPI-C is a retrospective interview covering 14 neuropsychiatric symptom domains. The NPI-C version of the NPI scale was designed to be administered by the clinician to the participant and the caregiver. The caregiver is first asked to provide frequency, severity, and distress ratings for each individual item across the domains. Frequency is rated on a scale from 0 to 4. Severity is rated on a scale from 0 to 3. Separately, the rater interviews the patient to assess frequency (0 to 4) of each item. Clinician rating of clinical impression is a severity rating (0 to 3) based on all available clinical and interview information. The score for the sleep disorders domain is the sum of clinical impression ratings of all items. There are 8 items in the sleep disorders domain. The minimum score for the sleep disorders domain is 0 and maximum score per domain is 24, with higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 6

07

Study locations

45 of 49 sites recruiting
  • Esperanza Clinical
    Murrieta, California 92562, United States
    Recruiting
  • Josephson Wallack Munshower Neurology PC
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
    Recruiting
  • Integrative Clinical Trials
    Brooklyn, New York 11229, United States
    Recruiting
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
    Recruiting
  • Insight Clinical Trials
    Independence, Ohio 44131, United States
    Recruiting
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
  • The Memory Clinic
    Bennington, Vermont 05201, United States
    Recruiting
  • Sunnybrook Health Sciences Centre
    North York, Ontario M4N 3M5, Canada
    Recruiting
  • Baycrest Centre for Geriatric Care
    North York, Ontario M6A 2E1, Canada
    Recruiting
  • Kawartha Centre
    Peterborough, Ontario K9H 294, Canada
    Recruiting
  • Ontario Shores Centre for Mental Health Sciences
    Whitby, Ontario L1N 5S9, Canada
    Not yet recruiting
  • Brain-Soultherapy s.r.o.
    Kladno, Central Bohemia 272 01, Czechia
    Recruiting
  • NeuropsychiatrieHK, sro
    Hradec Králové, Hradec Králové Region 500 02, Czechia
    Recruiting
  • Psychiatrie-Ambulance s.r.o
    Pilsen, Plzeň Region 301 00, Czechia
    Recruiting
  • FNUSA - St. Anne's University Hospital Brno
    Brno, South Moravian 602 00, Czechia
    Recruiting
  • Medicum Gesundheitszentrum Flugfeld - Praxis Bischof & Secheres
    Böblingen, Baden-Wurttemberg 71034, Germany
    Recruiting
  • Curiositas ad sanum Studien und Beratungs GmbH
    Ebersberg, Bavaria 85560, Germany
    Recruiting
  • TUM Klinikum rechts der Isar
    München, Bavaria 81675, Germany
    Not yet recruiting
  • Praxis Dr. med. Kirsten Hahn
    Berlin, State of Berlin 13187, Germany
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Rome, Lazio 00133, Italy
    Recruiting
  • Universita degli Studi di Roma ''La Sapienza" - Azienda Ospedaliera Sant'Andrea
    Rome, Lazio 00189, Italy
    Recruiting
  • Azienda Ospedaliera Cardinale Giovanni Panico
    Tricase, Lecce 73039, Italy
    Recruiting
  • IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
    Brescia, Lombardy 25125, Italy
    Recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Main Campus
    Milan, Lombardy 20122, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    Palermo, Sicily 90127, Italy
    Recruiting
  • Azienda Sanitaria Locale (ASL) Chieti - Ospedale Policlinico "SS Annunziata''
    Chieti, 66100, Italy
    Recruiting
  • Centrum Medyczne HCP Sp. z o.o.
    Poznan, Greater Poland Voivodeship 61-485, Poland
    Recruiting
  • Krakowska Akademia Neurologii
    Krakow, Lesser Poland Voivodeship 31-505, Poland
    Recruiting
  • NZOZ Wroclawskie Centrum Alzheimerowskie
    Wroclaw, Lower Silesian Voivodeship 53-659, Poland
    Recruiting
  • FutureMeds Wroclaw
    Wroclaw, Lower Silesian Voivodeship 53-673, Poland
    Recruiting
  • NZOZ Neuromed M. i M. Nastaj Spolka Partnerska
    Lublin, Lublin Voivodeship 20-064, Poland
    Recruiting
  • RCMed Oddzial Sochaczew
    Sochaczew, Masovian Voivodeship 69-500, Poland
    Recruiting
  • ETG Neuroscience Sp. z o.o.
    Warsaw, Masovian Voivodeship 02-677, Poland
    Recruiting
  • Silmedic Sp. z o.o.
    Katowice, Silesian Voivodeship 40-282, Poland
    Recruiting
  • Clinhouse Sp. z o.o.
    Zabrze, Silesian Voivodeship 41-807, Poland
    Recruiting
  • Velocity Clinical Research, Staszów
    Staszów, Świętokrzyskie Voivodeship 28-200, Poland
    Recruiting
  • MUDr. Beata Dupejova, Neurologicka Ambulancia S.r.o.
    Banská Bystrica, Banská Bystrica Region 974 04, Slovakia
    Recruiting
  • Univerzitna nemocnica Bratislava
    Bratislava, Bratislava Kraj 813 69, Slovakia
    Not yet recruiting
  • EPAMED s r.o.
    Košice, Košice Region 040 11, Slovakia
    Recruiting
  • Crystal Comfort S.R.O.
    Vranov nad Topľou, Presov 093 01, Slovakia
    Recruiting
  • Medicinske Centrum Konzilium, s.r.o.
    Dubnica nad Váhom, Trenčín Region 018 41, Slovakia
    Recruiting
  • Hospital Universitario Virgen de la Macarena
    Seville, Andalusia 41009, Spain
    Recruiting
  • Hospital Universitario Rio Hortega
    Valladolid, Castille and León 47012, Spain
    Recruiting
  • Hospital Virgen de la Concha
    Zamora, Castille and León 49029, Spain
    Recruiting
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, Catalonia 08916, Spain
    Not yet recruiting
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
    Recruiting
  • Scottish Brain Sciences
    Edinburgh, Midlothian EH12 5PJ, United Kingdom
    Recruiting
  • Scottish Brain Sciences
    Aberdeen, North East Scotland AB25 2XE, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 70. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 16, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Feb 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • Oregon Health & Science University · Portland, United StatesNot yet recruiting→Recruiting
  • Sunnybrook Health Sciences Centre · North York, CanadaNot yet recruiting→Recruiting
  • Baycrest Centre for Geriatric Care · North York, CanadaNot yet recruiting→Recruiting
  • Psychiatrie-Ambulance s.r.o · Pilsen, CzechiaNot yet recruiting→Recruiting
  • FNUSA - St. Anne's University Hospital Brno · Brno, CzechiaNot yet recruiting→Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata · Rome, ItalyNot yet recruiting→Recruiting
  • Universita degli Studi di Roma ''La Sapienza" - Azienda Ospedaliera Sant'Andrea · Rome, ItalyNot yet recruiting→Recruiting
  • NZOZ Neuromed M. i M. Nastaj Spolka Partnerska · Lublin, PolandNot yet recruiting→Recruiting
  • MUDr. Beata Dupejova, Neurologicka Ambulancia S.r.o. · Banská Bystrica, SlovakiaNot yet recruiting→Recruiting
  • EPAMED s r.o. · Košice, SlovakiaNot yet recruiting→Recruiting
  • Medicinske Centrum Konzilium, s.r.o. · Dubnica nad Váhom, SlovakiaNot yet recruiting→Recruiting
Show site
  • Azienda Sanitaria Locale (ASL) Chieti - Ospedale Policlinico "SS Annunziata'' · Chieti, Italy
Show 1 removed
  • Galen Research LLC · Chesterfield, United States
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added, 1 site removed. 11 sites changed recruiting status (11 now recruiting)
    Show 11 sites
    • Oregon Health & Science University · Portland, United StatesNot yet recruiting→Recruiting
    • Sunnybrook Health Sciences Centre · North York, CanadaNot yet recruiting→Recruiting
    • Baycrest Centre for Geriatric Care · North York, CanadaNot yet recruiting→Recruiting
    • Psychiatrie-Ambulance s.r.o · Pilsen, CzechiaNot yet recruiting→Recruiting
    • FNUSA - St. Anne's University Hospital Brno · Brno, CzechiaNot yet recruiting→Recruiting
    • Azienda Ospedaliera Universitaria Policlinico Tor Vergata · Rome, ItalyNot yet recruiting→Recruiting
    • Universita degli Studi di Roma ''La Sapienza" - Azienda Ospedaliera Sant'Andrea · Rome, ItalyNot yet recruiting→Recruiting
    • NZOZ Neuromed M. i M. Nastaj Spolka Partnerska · Lublin, PolandNot yet recruiting→Recruiting
    • MUDr. Beata Dupejova, Neurologicka Ambulancia S.r.o. · Banská Bystrica, SlovakiaNot yet recruiting→Recruiting
    • EPAMED s r.o. · Košice, SlovakiaNot yet recruiting→Recruiting
    • Medicinske Centrum Konzilium, s.r.o. · Dubnica nad Váhom, SlovakiaNot yet recruiting→Recruiting
    Show site
    • Azienda Sanitaria Locale (ASL) Chieti - Ospedale Policlinico "SS Annunziata'' · Chieti, Italy
    Show 1 removed
    • Galen Research LLC · Chesterfield, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284472
Lead sponsor
Exciva GmbH
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Feb 2, 2026
Primary completion
Jan 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Exciva Clinical Studies
Contact
studies@exciva.com
+49 6221-6479990

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion